(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 62.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.46%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Bridgebio Pharma's revenue in 2026 is $579,958,000.On average, 25 Wall Street analysts forecast BBIO's revenue for 2026 to be $195,238,403,250, with the lowest BBIO revenue forecast at $162,079,094,980, and the highest BBIO revenue forecast at $254,815,475,842. On average, 23 Wall Street analysts forecast BBIO's revenue for 2027 to be $329,830,331,528, with the lowest BBIO revenue forecast at $265,391,982,910, and the highest BBIO revenue forecast at $474,180,066,882.
In 2028, BBIO is forecast to generate $491,024,133,694 in revenue, with the lowest revenue forecast at $391,918,345,242 and the highest revenue forecast at $638,311,787,678.